Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
- Status
- COMPLETED
- Phase
- PHASE1
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Food Effect and CYP1A2 Induction Study in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 QT Study in Healthy Male Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
- Status
- COMPLETED
- Phase
- PHASE2
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males
- Status
- COMPLETED
- Phase
- PHASE1